Silibinin attenuates adipose tissue inflammation and reverses obesity and its complications in diet-induced obesity model in mice

Autor: Shifa Bdour, Nidal A. Qinna, Karem H. Alzoubi, Qutaibah Ababneh, Mohammad Alsaggar, Tamam El-Elimat
Rok vydání: 2019
Předmět:
Male
Anti-Inflammatory Agents
Adipose tissue
Gene Expression
Glucose homeostasis
chemistry.chemical_compound
0302 clinical medicine
Hyperinsulinemia
Adipocytes
Pharmacology (medical)
0303 health sciences
Glucose tolerance test
medicine.diagnostic_test
Fatty liver
Adipose Tissue
Liver
030220 oncology & carcinogenesis
Research Article
medicine.medical_specialty
Silibinin
Diet
High-Fat
Anti-inflammatory therapy
03 medical and health sciences
Insulin resistance
lcsh:RA1190-1270
Fatty liver disease
Internal medicine
medicine
Animals
Obesity
030304 developmental biology
lcsh:Toxicology. Poisons
Pharmacology
business.industry
Hypertriglyceridemia
lcsh:RM1-950
Body Weight
Hypertrophy
medicine.disease
Mice
Inbred C57BL
Disease Models
Animal
Endocrinology
lcsh:Therapeutics. Pharmacology
Glucose
chemistry
Silybin
Anti-Obesity Agents
business
Zdroj: BMC Pharmacology & Toxicology
BMC Pharmacology and Toxicology, Vol 21, Iss 1, Pp 1-8 (2020)
ISSN: 2050-6511
Popis: Background Obesity is a multifactorial chronic disease that comprises several pathological events, such as adipose hypertrophy, fatty liver and insulin resistance. Inflammation is a key contributer to development of these events, and therefore, targeting inflammation is increasingly considered for management of obesity and its complications. The aim of the current study was to investigate therapeutic outcomes of anti-inflammatory activities of the natural compound Silibinin in reversing obesity and its complication in mice. Methods C57BL/6 male mice were fed high-fat diet for 8 weeks until development of obesity, and then injected with 50 mg/kg silibinin intraperitoneally twice per week, or vehicle for 8 weeks. Throughout the experiment, mice were continuously checked for body weight and food intake, and glucose tolerance test was performed toward the end of the experiment. Animals were sacrificed and serum and tissues were collected for biochemical, histological, and gene expression analysis to assess silibinin effects on adipose inflammation, fat accumulation, liver adipogenesis and glucose homeostasis. Results Silibinin treatment reversed adipose tissue inflammation and adipocyte hypertrophy, and blocked progression in weight gain and obesity development with no significant effects on rates of food intake. Silibinin also reversed fatty liver disease and restored glucose homeostasis in treated animals, and reversed hyperglycemia, hyperinsulinemia and hypertriglyceridemia. Conclusion In this study, we demonstrated that silibinin as an anti-inflammatory therapy is a potential alternative to manage obesity, as well as its related complications. Moreover, silibinin-based therapies could further evolve as a novel treatment to manage various inflammation-driven disorders.
Databáze: OpenAIRE
Externí odkaz: